Improving the Overall Safety and Quality of Care for Your Patients with Metastatic Hormone-Sensitive Prostate Cancer: How Does Your Approach Compare with the Experts?

Podcast 3: Disparities in Access to Novel Therapies in Metastatic Hormone-Sensitive Prostate Cancer
Post-Test/Evaluation

Exit Survey

Questions marked with a * are required

21%

Contact Information

First Name

Last Name

Email Address

Credentials/Degree (MD, DO, etc.)

Date of Participation

Interim results from the PANTHER study investigating the effects of a novel hormonal therapy combination of apalutamide and abiraterone plus prednisone, in advanced prostate cancer, demonstrated that compared to their white counterparts, black patients:

Exhibited significantly longer radiographic progression-free and overall survival

Experienced lower rates of toxicity

Had comparable overall survival rates

Were more likely to have received prior docetaxel

No differences observed

A 65-year-old man with a history of localized prostate cancer treated with radical prostatectomy presents with bone pain and elevated prostate-specific antigen (PSA) levels. Bone scan and imaging studies reveals 3 bone lesions in the spine and lymph node involvement. What is the most appropriate treatment for this patient?

Androgen deprivation therapy (ADT) plus abiraterone and prednisone

ADT plus enzalutamide

ADT monotherapy

Primary radiotherapy to the prostate in combination with ADT.

a or b

All of the following are potential barriers to equitable access to novel hormonal therapies for patients with metastatic hormone-sensitive prostate cancer (mHSPC) except?

Lack of clinical trials or evidence to support the use of novel hormonal therapies in mHSPC

Lack of insurance coverage or financial assistance for novel hormonal therapies

Lack of awareness or education about novel hormonal therapies among patients and providers

Lack of availability or supply of novel hormonal therapies in certain regions or settings